Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Athira Pharma CEO steps down in the wake of research misconduct allegations

By Brian Buntz | October 22, 2021

Athira PharmaShares of Athira Pharma (NSDQ:ATHA) jumped 9.35% in mid-day trading after the company announced the resignation of embattled CEO Leen Kawas.

Kawas will also give up her seat on the Bothell, Washington–based company’s board.

Facing allegations that she doctored a series of images in research papers, Leen Kawas was placed on leave in June.

Several papers she co-authored at the Journal of Pharmacology and Experimental Therapeutics received expressions of concern regarding the possibility of manipulated images.

 Mark J. Litton, PhD, MBA

Mark J. Litton

An internal investigation recently concluded that Kawas had doctored images in several research papers she authored or co-authored while at Washington State University, the company said in a news release. Kawas received a Ph.D. in molecular pharmacology from the university in 2011.

Mark Litton will serve as CEO of Athira. Litton, formerly the company’s chief operating officer, has been interim CEO since June.

The company had previously announced that its lead candidate ATH-1017 demonstrated a statistically significant improvement in a Phase 1a/b study. The trial used an objective measure of working memory processing speed in Alzheimer’s disease patients. An independent CRO performed the The Phase 1a/b trial and an independent auditing firm confirmed GCP compliance and data management quality of the Phase study.

Although the company’s stock is trending upward, its shares lost approximately half of their value in mid-June when Athira announced it placed Kawas on leave.

The company is also facing a smattering of shareholder rights investigations and lawsuits.


Filed Under: clinical trials, Drug Discovery, Neurological Disease
Tagged With: Alzheimer’s, ATH-1017, Athira Pharma, Leen Kawas, Mark J. Litton
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50